Приказ основних података о документу

dc.creatorRužić, Dušan
dc.creatorNikolić, Katarina
dc.creatorAgbaba, Danica
dc.creatorGanesan, A.
dc.date.accessioned2023-09-15T09:39:10Z
dc.date.available2023-09-15T09:39:10Z
dc.date.issued2016
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5028
dc.description.abstractHistone deacetylases (HDACs) are epigenetic erasers, which are considered as transcriptional repressors and potent anticancer targets. Today, 18 human HDACs are identified and divided in four classes. FDA has approved four Histone Deacetylase Inhibitors (HDACi), defined as pan-HDAC inhibitors...sr
dc.language.isoensr
dc.publisherFreiburg Institute for Advanced Studiessr
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172033/RS//sr
dc.relationCOST CM1406 actionsr
dc.rightsrestrictedAccesssr
dc.source3rd Freiburg Epigenetic Spring Meeting and COST Action EpiChemBio CM1406, Freiburg, April 10-13sr
dc.titleComputer aided drug design – a step closer to selective HDAC-6 inhibitor?sr
dc.typeconferenceObjectsr
dc.rights.licenseARRsr
dc.description.otherPoster
dc.identifier.rcubhttps://hdl.handle.net/21.15107/rcub_farfar_5028
dc.type.versionpublishedVersionsr


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу